US FDA approves Moderna’s mRNA flu vaccine
The US FDA approved Moderna’s mRNA flu vaccine mFlusiva for people aged 50 and older, Moderna said. Reuters reported traditional approval for ages 50 to 64 and accelerated approval for 65+. Based on a late-stage trial of 40,000+ adults, it was 26.6% more effective than a licensed standard-dose flu vaccine. Moderna plans more data for 65+ and faces competition from Sanofi, GSK, CSL Seqirus and AstraZeneca.
How this was made
The 30-second read
Why it matters
This is a regulatory milestone that can improve Moderna’s vaccine credibility and future update cadence claims, but the article flags delayed commercialization due to contracting-cycle timing.
Market read
Traders can reprice Moderna’s vaccine platform odds on FDA approval, while also discounting near-term revenue impact due to the 2026 season miss.
What to watch
Competitive dynamics versus established high-dose flu offerings (Sanofi, GSK, CSL Seqirus, AstraZeneca) and the need for additional 65+ study data could affect uptake and label confidence.
Background
The FDA approval makes mFlusiva the first seasonal flu vaccine using mRNA technology to receive FDA approval, with traditional approval for 50-64 and accelerated approval for 65+.
Ticker impact
FDA approved Moderna’s mRNA flu vaccine mFlusiva for adults 50+, including accelerated approval for ages 65+.
Likely supportive for sentiment and platform valuation, with limited immediate earnings impact given the 2026 season miss.
The article is a first FDA approval report and includes efficacy/age-label details, but also notes no significant revenue until 2H 2027 due to contracting-cycle timing.
Market effects
Strengthens the mRNA vaccine platform narrative versus conventional egg-based flu vaccines, potentially raising competitive pressure on incumbents.
Primarily US regulatory-driven, with potential spillover to global vaccine supply and partner expectations.
US approval can influence international adoption timelines and future seasonal flu program planning.
Counterpoint
The approval may not translate into near-term financial upside because Moderna missed the 2026 contracting cycle and expects meaningful revenue only in 2H 2027.
Key entities
- companyModerna
mRNA vaccine developer receiving FDA approval for mFlusiva for adults 50+.
- regulatorUS Food and Drug Administration (FDA)
Approved mFlusiva, including accelerated approval for ages 65+.
- productmFlusiva
Moderna’s mRNA-based seasonal flu vaccine.
- companySanofi
Comparator in the article’s antibody-response data versus Sanofi’s high-dose flu vaccine.
